Cargando…

Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland

BACKGROUND: Increasing reports of multidrug resistance (MDR) in clinical Pseudomonas aeruginosa have led to a necessity for new antimicrobials. Ceftazidime-avibactam (CZA) is indicated for use against MDR P. aeruginosa across a broad range of infection types and particularly those that are carbapene...

Descripción completa

Detalles Bibliográficos
Autores principales: Babouee Flury, Baharak, Bösch, Anja, Gisler, Valentin, Egli, Adrian, Seiffert, Salome N., Nolte, Oliver, Findlay, Jacqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166991/
https://www.ncbi.nlm.nih.gov/pubmed/37180441
http://dx.doi.org/10.3389/fcimb.2023.1098944
_version_ 1785038566158499840
author Babouee Flury, Baharak
Bösch, Anja
Gisler, Valentin
Egli, Adrian
Seiffert, Salome N.
Nolte, Oliver
Findlay, Jacqueline
author_facet Babouee Flury, Baharak
Bösch, Anja
Gisler, Valentin
Egli, Adrian
Seiffert, Salome N.
Nolte, Oliver
Findlay, Jacqueline
author_sort Babouee Flury, Baharak
collection PubMed
description BACKGROUND: Increasing reports of multidrug resistance (MDR) in clinical Pseudomonas aeruginosa have led to a necessity for new antimicrobials. Ceftazidime-avibactam (CZA) is indicated for use against MDR P. aeruginosa across a broad range of infection types and particularly those that are carbapenem resistant. This study sought to determine the molecular mechanisms of CZA and imipenem (IPM)-resistance in clinical P. aeruginosa isolates obtained from Swiss hospitals. METHODS: Clinical P. aeruginosa isolates were obtained from inpatients in three hospitals in Switzerland. Susceptibility was determined by either antibiotic disc testing or broth microdilution according to EUCAST methodology. AmpC activity was determined using cloxacillin and efflux activity was determined using phenylalanine-arginine β-naphthylamide, in agar plates. Whole Genome Sequencing was performed on 18 clinical isolates. Sequence types (STs) and resistance genes were ascertained using the Centre for Genomic Epidemiology platform. Genes of interest were extracted from sequenced isolates and compared to reference strain P. aeruginosa PAO1. RESULTS: Sixteen different STs were identified amongst the 18 isolates in this study indicating a high degree of genomic diversity. No carbapenemases were detected but one isolate did harbor the ESBL bla (PER-1). Eight isolates were CZA-resistant with MICs ranging from 16-64 mg/L, and the remaining ten isolates had either low/wildtype MICs (n=6; 1-2 mg/L) or elevated, but still susceptible, MICs (n=4; 4-8 mg/L). Ten isolates were IPM-resistant, seven of which had mutations resulting in truncations of OprD, and the remaining nine IPM-susceptible isolates had intact oprD genes. Within CZA-R isolates, and those with reduced susceptibility, mutations resulting in ampC derepression, OprD loss, mexAB overexpression and ESBL (bla (PER-1)) carriage were observed in various combinations and one harbored a truncation of the PBP4 dacB gene. Within the six isolates with wildtype-resistance levels, five had no mutations that would affect any antimicrobial resistance (AMR) genes of interest when compared to PAO1. CONCLUSION: This preliminary study highlights that CZA-resistance in P. aeruginosa is multifactorial and could be caused by the interplay between different resistance mechanisms including ESBL carriage, increased efflux, loss of permeability and derepression of its intrinsic ampC.
format Online
Article
Text
id pubmed-10166991
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101669912023-05-10 Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland Babouee Flury, Baharak Bösch, Anja Gisler, Valentin Egli, Adrian Seiffert, Salome N. Nolte, Oliver Findlay, Jacqueline Front Cell Infect Microbiol Cellular and Infection Microbiology BACKGROUND: Increasing reports of multidrug resistance (MDR) in clinical Pseudomonas aeruginosa have led to a necessity for new antimicrobials. Ceftazidime-avibactam (CZA) is indicated for use against MDR P. aeruginosa across a broad range of infection types and particularly those that are carbapenem resistant. This study sought to determine the molecular mechanisms of CZA and imipenem (IPM)-resistance in clinical P. aeruginosa isolates obtained from Swiss hospitals. METHODS: Clinical P. aeruginosa isolates were obtained from inpatients in three hospitals in Switzerland. Susceptibility was determined by either antibiotic disc testing or broth microdilution according to EUCAST methodology. AmpC activity was determined using cloxacillin and efflux activity was determined using phenylalanine-arginine β-naphthylamide, in agar plates. Whole Genome Sequencing was performed on 18 clinical isolates. Sequence types (STs) and resistance genes were ascertained using the Centre for Genomic Epidemiology platform. Genes of interest were extracted from sequenced isolates and compared to reference strain P. aeruginosa PAO1. RESULTS: Sixteen different STs were identified amongst the 18 isolates in this study indicating a high degree of genomic diversity. No carbapenemases were detected but one isolate did harbor the ESBL bla (PER-1). Eight isolates were CZA-resistant with MICs ranging from 16-64 mg/L, and the remaining ten isolates had either low/wildtype MICs (n=6; 1-2 mg/L) or elevated, but still susceptible, MICs (n=4; 4-8 mg/L). Ten isolates were IPM-resistant, seven of which had mutations resulting in truncations of OprD, and the remaining nine IPM-susceptible isolates had intact oprD genes. Within CZA-R isolates, and those with reduced susceptibility, mutations resulting in ampC derepression, OprD loss, mexAB overexpression and ESBL (bla (PER-1)) carriage were observed in various combinations and one harbored a truncation of the PBP4 dacB gene. Within the six isolates with wildtype-resistance levels, five had no mutations that would affect any antimicrobial resistance (AMR) genes of interest when compared to PAO1. CONCLUSION: This preliminary study highlights that CZA-resistance in P. aeruginosa is multifactorial and could be caused by the interplay between different resistance mechanisms including ESBL carriage, increased efflux, loss of permeability and derepression of its intrinsic ampC. Frontiers Media S.A. 2023-04-25 /pmc/articles/PMC10166991/ /pubmed/37180441 http://dx.doi.org/10.3389/fcimb.2023.1098944 Text en Copyright © 2023 Babouee Flury, Bösch, Gisler, Egli, Seiffert, Nolte and Findlay https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Babouee Flury, Baharak
Bösch, Anja
Gisler, Valentin
Egli, Adrian
Seiffert, Salome N.
Nolte, Oliver
Findlay, Jacqueline
Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
title Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
title_full Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
title_fullStr Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
title_full_unstemmed Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
title_short Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland
title_sort multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical pseudomonas aeruginosa isolates from switzerland
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166991/
https://www.ncbi.nlm.nih.gov/pubmed/37180441
http://dx.doi.org/10.3389/fcimb.2023.1098944
work_keys_str_mv AT baboueeflurybaharak multifactorialresistancemechanismsassociatedwithresistancetoceftazidimeavibactaminclinicalpseudomonasaeruginosaisolatesfromswitzerland
AT boschanja multifactorialresistancemechanismsassociatedwithresistancetoceftazidimeavibactaminclinicalpseudomonasaeruginosaisolatesfromswitzerland
AT gislervalentin multifactorialresistancemechanismsassociatedwithresistancetoceftazidimeavibactaminclinicalpseudomonasaeruginosaisolatesfromswitzerland
AT egliadrian multifactorialresistancemechanismsassociatedwithresistancetoceftazidimeavibactaminclinicalpseudomonasaeruginosaisolatesfromswitzerland
AT seiffertsalomen multifactorialresistancemechanismsassociatedwithresistancetoceftazidimeavibactaminclinicalpseudomonasaeruginosaisolatesfromswitzerland
AT nolteoliver multifactorialresistancemechanismsassociatedwithresistancetoceftazidimeavibactaminclinicalpseudomonasaeruginosaisolatesfromswitzerland
AT findlayjacqueline multifactorialresistancemechanismsassociatedwithresistancetoceftazidimeavibactaminclinicalpseudomonasaeruginosaisolatesfromswitzerland